Wednesday - October 24, 2018
2018 winners of the Global Ophthalmology Award Programme announced
Friday - September 28, 2018
Protecting patient access to licensed and NICE recommended treatments for wet age-related macular degeneration
Following the judicial review judgment on 21 September, the High Court has decided that in certain circumstances it is lawful to offer patients bevacizumab injections for the treatment of wet age-related macular degeneration (wet AMD) in preference to approved licensed treatments, even though bevacizumab is not manufactured or licensed for use in the eye.
Friday - September 21, 2018